HIV-1 Vpu triggers the cleavage of TDP-43 by stimulating Caspase 3 activation. The cleavage products generated can induce the ...
A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...
The findings, published in Nature Immunology, indicate that tumors edit the activity of multiple genes to avoid immune ...
Monday revealed positive data from the CABINET, a phase 3 pivotal trial evaluating Cabozantinib versus placebo ...
PEACE-3 trial results reveal that Enzalutamide combined with Radium-223 improves survival outcomes in prostate cancer ...
Cancer patients with wasting syndrome have gained weight after taking Pfizer’s anti-GDF-15 antibody in a midphase study, ...
BARCELONA, Spain — Adding a second immunotherapy from Bristol Myers Squibb to an existing checkpoint inhibitor and ...
Researchers have identified five independent factors that predict cancer patients' response to checkpoint inhibitors (CPIs). The study validates these factors in more than 1,400 patients and diverse ...
Trial investigating Cabometyx® (cabozantinib) in combination with atezolizumab demonstrated a positive trend towards improvement for one of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback